Gene Therapy in Hearing Loss Treatment: A Review
Journal of Otorhinolaryngology and Facial Plastic Surgery,
Vol. 6 No. 1 (2020),
12 September 2020
Background Hearing loss, which is highly heterogeneous, is the most common sensorineural disorder in humans. More than 50% of the causes of deafness are attributed to genetic factors. Numerous studies have shown the persistent negative impact of deafness on communication and quality of life. Therefore, action to optimize performance and maintain or improve hearing ability seems necessary. In so doing, interventions are performed after assessing hearing loss. The most important intervention is gene therapy; For several genetic diseases, gene therapy is a potential treatment that is being investigated. Gene therapy will restore the ability to hear by overcoming functional defects caused by genetic mutations. Furthermore, gene therapy might potentially be used to trigger the regeneration of hair cells by transferring genes required in the cochlea for hair cell differentiation.
Aim: We review recent research about hereditary hearing loss and technologies in animal.
Methods: In this study, we review current reports in clarifying genomics of hereditary hearing loss and technologies between 2014 and 2020 in PubMed, Scopus, and Google Scholar to create a gene therapy that may soon become a treatment choice. We also discuss recent research applied to animal models of hearing loss by gene therapy.
Conclusion: Gene therapy allows for the treatment of sensorineural hearing loss by restoring and/or preserving the inner ear cells functioning. Hopeful results from recent research have contributed to cochlear gene therapies being created for end-use in patients.
- Hearing loss; Inner ear; Gene therapy; Genomics.
How to Cite
2. World Health Organization. Deafness and hearing loss. Geneva: World Health Organization, 2020. Accessed 2020 March 1. Available from: https://www.who.int/news-room/ fact-sheets/detail/deafness-and-hearing-loss.
3. Carpena NT, Lee MY. Genetic hearing loss and gene therapy. Genomics & Informatics. 2018 Dec;16(4).
4. Oshima K, Grimm CM, Corrales CE, Senn P, Monedero RM, Géléoc GS, et al. Differential distribution of stem cells in the auditory and vestibular organs of the inner ear. Journal of the Association for Research in Otolaryngology. 2007 Mar 1;8(1):18-31.
5. Kelley MW, Driver EC, Puligilla C. Regulation of cell fate and patterning in the developing mammalian cochlea. Current opinion in otolaryngology & head and neck surgery. 2009 Oct;17(5):381.
6. Sinkkonen ST, Chai R, Jan TA, Hartman BH, Laske RD, Gahlen F, et al. Intrinsic regenerative potential of murine cochlear supporting cells. Scientific reports. 2011 Jun 29;1:26.
7. Chien WW, Monzack EL, McDougald DS, Cunningham LL. Gene therapy for sensorineural hearing loss. Ear and hearing. 2015 Jan 1;36(1):1-7.
8. Dalton DS, Cruickshanks KJ, Klein BE, Klein R, Wiley TL, Nondahl DM. The impact of hearing loss on quality of life in older adults. The gerontologist. 2003 Oct 1;43(5):661-8.
9. Gordon-Salant S. Hearing loss and aging: new research findings and clinical implications. Journal of Rehabilitation Research & Development. 2005 Jul 2;42.
10. Petit C, Levilliers J, Hardelin JP. Molecular genetics of hearing loss. Annual review of genetics. 2001 Dec;35(1):589-645.
11. Chia EM, Wang JJ, Rochtchina E, Cumming RR, Newall P, Mitchell P. Hearing impairment and health-related quality of life: the Blue Mountains Hearing Study. Ear and hearing. 2007 Apr 1;28(2):187-95.
12. Strawbridge WJ, Wallhagen MI, Shema SJ, Kaplan GA. Negative consequences of hearing impairment in old age: a longitudinal analysis. The Gerontologist. 2000 Jun 1;40(3):320-6.
13. Ahmed H, Shubina-Oleinik O, Holt JR. Emerging gene therapies for genetic hearing loss. Journal of the Association for Research in Otolaryngology. 2017 Oct 1;18(5):694-70.
14. Van Camp G, Smith RJ. Hereditary Hearing Loss Homepage. The Authors: Hereditary Hearing Loss Homepage, 2020. Accessed 2020 Nov 20. Available from: https://www. hereditaryhearingloss.org.
15. Sinnathuray AR, Raut V, Awa A, Magee A, Toner JG. A review of cochlear implantation in mitochondrial sensorineural hearing loss. Otology & neurotology. 2003 May 1;24(3):418-26.
16. Lenz DR, Avraham KB. Hereditary hearing loss: from human mutation to mechanism. Hearing research. 2011 Nov 1;281(1-2):3-10.
17. Duan M, Venail F, Spencer N, Mezzina M. Treatment of peripheral sensorineural hearing loss: gene therapy. Gene therapy. 2004 Oct;11(1):S51-6.
18. Zheng JL, Gao WQ. Overexpression of Math1 induces robust production of extra hair cells in postnatal rat inner ears. Nature neuroscience. 2000 Jun;3(6):580-6.
19. Schneider ME, Belyantseva IA, Azevedo RB, Kachar B. Rapid renewal of auditory hair bundles. Nature. 2002 Aug;418(6900):837-8.
20. Verma IM, Naldini L, Kafri T, Miyoshi H, Takahashi M, Blömer U, et al. Gene therapy: promises, problems and prospects. InGenes and Resistance to Disease 2000 (pp. 147-157). Springer, Berlin, Heidelberg.
21. Duan ML, Ulfendahl M, Laurell G, Counter AS, Pyykkö I, Borg E, et al. Protection and treatment of sensorineural hearing disorders caused by exogenous factors: experimental findings and potential clinical application. Hearing research. 2002 Jul 1;169(1-2):169-78.
22. Hess A, Labbé D, Michel O, Teranishi MA, Orzechowska O, Schmidt A, et al. In vitro activation of extracellular signal-regulated kinase1/2 in the inner ear of guinea pigs. Brain research. 2002 Nov 29;956(2):236-45.
23. Luebke AE, Steiger JD, Hodges BL, Amalfitano A. A modified adenovirus can transfect cochlear hair cells in vivo without compromising cochlear function. Gene therapy. 2001 May;8(10):789-94.
24. Kawamoto K, Yagi M, Stöver T, Kanzaki S, Raphael Y. Hearing and hair cells are protected by adenoviral gene therapy with TGF-β1 and GDNF. Molecular Therapy. 2003 Apr 1;7(4):484-92.
25. Hakuba N, Watabe K, Hyodo J, Ohashi T, Eto Y, Taniguchi M, et al. Adenovirus-mediated overexpression of a gene prevents hearing loss and progressive inner hair cell loss after transient cochlear ischemia in gerbils. Gene therapy. 2003 Mar;10(5):426-33.
26. Agrawal RS, Muangman S, Layne MD, Melo L, Perrella MA, Lee RT, et al. Pre-emptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survival. Gene therapy. 2004 Jun;11(12):962-9.
27. Blair GE. Adenoviral vectors, breaking a barrier to gene therapy? GENE THERAPY-BASINGSTOKE-. 2004 Feb 1;11(3):229-30.
28. Lalwani AK, Walsh BJ, Reilly PG, Carvalho GJ, Zolotukhin S, Muzyczka N, et al. Long-term in vivo cochlear transgene expression mediated by recombinant adeno-associated virus. Gene therapy. 1998 Feb;5(2):277-81.
29. Miller JM, Chi DH, O'Keeffe LJ, Kruszka P, Raphael Y, Altschuler RA. Neurotrophins can enhance spiral ganglion cell survival after inner hair cell loss. International Journal of Developmental Neuroscience. 1997 Jul;15(4-5):631-43.
30. Luebke AE, Foster PK, Muller CD, Peel AL. Cochlear function and transgene expression in the guinea pig cochlea, using adenovirus-and adeno-associated virus-directed gene transfer. Human gene therapy. 2001 May 1;12(7):773-81.
31. Staecker H, Li D, O'Malley Jr BW, Van De Water TR. Gene expression in the mammalian cochlea: a study of multiple vector systems. Acta oto-laryngologica. 2001 Jan 1;121(2):157-63.
32. Bowers WJ, Chen X, Guo H, Frisina DR, Federoff HJ, Frisina RD. Neurotrophin-3 transduction attenuates cisplatin spiral ganglion neuron ototoxicity in the cochlea. Molecular Therapy. 2002 Jul 1;6(1):12-8.
33. Han JJ, Mhatre AN, Wareing M, Pettis R, Gao WQ, Zufferey RN, et al. Transgene expression in the guinea pig cochlea mediated by a lentivirus-derived gene transfer vector. Human gene therapy. 1999 Jul 20;10(11):1867-73.
34. Miwa T, Minoda R, Ise M, Yamada T, Yumoto E. Mouse otocyst transuterine gene transfer restores hearing in mice with connexin 30 deletion-associated hearing loss. Molecular Therapy. 2013 Jun 1;21(6):1142-50.
35. Fukui H, Raphael Y. Gene therapy for the inner ear. Hearing research. 2013 Mar 1;297:99-105.
36. Akil O, Seal RP, Burke K, Wang C, Alemi A, During M, et al. Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy. Neuron. 2012 Jul 26;75(2):283-93.
37. Seal RP, Akil O, Yi E, Weber CM, Grant L, Yoo J, et al. Sensorineural deafness and seizures in mice lacking vesicular glutamate transporter 3. Neuron. 2008 Jan 24;57(2):263-75.
38. Yu Q, Wang Y, Chang Q, Wang J, Gong S, Li H, et al. Virally expressed connexin26 restores gap junction function in the cochlea of conditional Gjb2 knockout mice. Gene therapy. 2014 Jan;21(1):71-80.
39. Choi BY, Kim HM, Ito T, Lee KY, Li X, Monahan K, et al. Mouse model of enlarged vestibular aqueducts defines temporal requirement of Slc26a4 expression for hearing acquisition. The Journal of clinical investigation. 2011 Oct 3;121(11).
40. Kawashima Y, Kurima K, Pan B, Griffith AJ, Holt JR. Transmembrane channel-like (TMC) genes are required for auditory and vestibular mechanosensation. Pflügers Archiv-European Journal of Physiology. 2015 Jan 1;467(1):85-94.
41. Askew C, Rochat C, Pan B, Asai Y, Ahmed H, Child E, et al. Tmc gene therapy restores auditory function in deaf mice. Science translational medicine. 2015 Jul 8;7(295):295ra108-.
- Abstract Viewed: 110 times
- PDF Downloaded: 116 times